Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026)
Fortrea Holdings' (FTRE) quarterly Cost of Revenue came in at $539.0 million in Q2 2026, down 6.55% YoY from $576.8 million in Q2 2025, and up 5.09% on a QoQ basis from $512.9 million in Q1 2026.
Analysis
Fortrea Holdings (FTRE) Cost of Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings (FTRE) has 5 years of Cost of Revenue data on file, last reported at $539.0 million in Q2 2026.
- Quarterly Cost of Revenue fell 6.55% year-over-year to $539.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $2.2 billion (down 1.57% YoY) and the FY2025 annual result came in at $2.2 billion, up 2.65% from the prior year.
- Cost of Revenue climbed to $539.0 million in Q2 2026, from $512.9 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $614.3 million in Q2 2022 to a low of $265.0 million in Q4 2022.
- A 5-year average of $538.8 million and a median of $554.2 million in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2023 — Cost of Revenue jumped 118.08% — and 2024, when it dropped 7.63%.
- Tracing FTRE's Cost of Revenue over 5 years: stood at $265.0 million in 2022, then jumped by 118.08% to $577.9 million in 2023, then declined by 3.77% to $556.1 million in 2024, then fell by 4.8% to $529.4 million in 2025, then increased by 1.81% to $539.0 million in 2026.
- The last three Cost of Revenue figures came in at $539.0 million (Q2 2026), $512.9 million (Q1 2026), and $529.4 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | 93.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 174.53 Mn |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Fortrea Holdings | 1.72 Bn | 1.55 Bn | 139.20 Mn | 539.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 539.00 Mn |
| Mar 31, 2026 | 512.90 Mn |
| Dec 31, 2025 | 529.40 Mn |
| Sep 30, 2025 | 578.60 Mn |
| Jun 30, 2025 | 576.80 Mn |
| Mar 31, 2025 | 534.80 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Sep 30, 2024 | 526.60 Mn |
| Jun 30, 2024 | 525.30 Mn |
| Mar 31, 2024 | 554.20 Mn |
| Dec 31, 2023 | 577.90 Mn |
| Sep 30, 2023 | 563.80 Mn |
| Jun 30, 2023 | 568.70 Mn |
| Mar 31, 2023 | 541.50 Mn |
| Dec 31, 2022 | 265.00 Mn |
| Sep 30, 2022 | 594.80 Mn |
| Jun 30, 2022 | 614.30 Mn |